Reaferon-LIPINT - instructions for use, dose, side effects, contraindications

in one capsule contains: active substance - interferon alfa-2b human recombinant - 500 000 ME; Excipients: sodium chloride - 8.01 mg sodium phosphate dibasic 12-water (sodium phosphate dodecahydrate) - 4.52 mg sodium phosphate monobasic aqueous 2 (sodium dihydrogen phosphate dihydrate) - 0.56 mg, lipoids C 100 (phosphatidylcholine) - 41.18 mg cholesterol - 4.53 mg alpha-tocopherol atsetet (vitamin E) - 0.56 mg lactose monohydrate - 91.34 mg colloidal anhydrous silica - 7,54mg (no more than 5%); composition of the capsule (body and lid): titanium dioxide (E 171) - 2%, gelatin - up to 100%.

Description:Capsules hard gelatinous white. The contents of the capsules are a fine crystalline powder of white color or white with a yellowish hue of color. Hygroscopic.

Pharmacotherapeutic group:MIBP is a cytokine.

ATX: & nbsp

L.03.A.B.05 Interferon alfa-2b

Pharmacodynamics:The drug has an immunomodulatory and antiviral effect. Interferon alfa-2b, recombinant human being in the active substance preparation is synthesized bacterial cells of the strain Escherichia coli SG-20050 / pIF16, a genetic unit which is integrated gene of human alpha-2b interferon.It is a protein containing 165 amino acids, and is identical in characteristics and properties to human leukocyte interferon alpha-2b.

The antiviral effect of interferon alfa-2b is manifested during the reproduction of the virus by active incorporation into the metabolic processes of the cells. Interferon, interacting with specific receptors on the surface of cells, initiates a number of intracellular changes, including the synthesis of specific cytokines and enzymes (2-5-adenylate synthetase and protein kinase), the action of which inhibits the formation of viral protein and viral ribonucleic acid in the cell.

The immunomodulatory effect of interferon alfa-2b is manifested in an increase in phagocytic activity of macrophages, enhancement of specific cytotoxic action of lymphocytes on target cells, changes in the quantitative and qualitative composition of secreted cytokines; changes in the functional activity of immunocompetent cells; changes in the production and secretion of intracellular proteins.

Indications:

Treatment of influenza and other acute respiratory viral diseases in adults as part of complex therapy.

Prevention of influenza and other acute respiratory viral diseases in adults during epidemics and seasonal morbidity.

Contraindications:

- children's age till 18 years;

- pregnancy;

- lactation period;

- lactase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome;

- hypersensitivity to interferon or any other components of the drug.

Carefully:Renal and / or hepatic insufficiency, expressed myelosuppression.

Pregnancy and lactation:The drug is contraindicated for use in pregnancy and lactation.

Dosing and Administration:

The drug is taken orally, 30 minutes before meals.

In the treatment of influenza and ARVI - 500 000 ME (1 capsule) daily 2 times a day for 5 days.

For the prevention of influenza and ARVI - 500 ME (1 capsule) per day, 2 times a week for a month.

If swallowing is difficult, capsules are carefully opened and the contents taken with a small amount of water.

Side effects:Allergic reactions are possible, flu-like syndrome (chills, fever, fatigue, lethargy, headache, myalgia, arthralgia, decreased appetite).

Overdose:There were no cases of drug overdose. It is possible to increase dose-dependent side effects. Treatment is symptomatic.

Interaction:

Interferon alfa is able to reduce the activity of P-450 cytochromes and, consequently, affect the metabolism of cimetidine, phenytoin, curantyl, theophylline, diazepam, propranolol, warfarin, and some cytostatics. May enhance neurotoxic, myelotoxic or cardiotoxic effects of drugs administered earlier or simultaneously with it. It should avoid joint use with drugs that depress the central nervous system, immunosuppressive drugs (including oral and parenteral forms of corticosteroids).

Drinking alcohol during treatment is not recommended.

Special instructions:In case of allergic reactions, it is necessary to consult a doctor.

Effect on the ability to drive transp. cf. and fur:

The use of the drug does not affect the ability to drive a vehicle or potentially dangerous mechanisms.

Form release / dosage:

Capsules, 500 000 ME.

Packaging:

For 10 or 20 capsules in bottles of high-density polyethylene (LDPE), sealed with a lid of PVD.

1 bottle with instructions for use in a cardboard box.

Storage conditions:Store in a dark place at a temperature of no higher than 8 ° C. Keep out of the reach of children.

Shelf life:

2 years. Not applicable after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LP-001611

Date of registration:28.03.2012

Date of cancellation:2017-03-28

The owner of the registration certificate:VECTOR-MEDICA, CJSC VECTOR-MEDICA, CJSC Russia

Manufacturer: & nbsp

VECTOR-MEDICA, CJSC Russia

Information update date: & nbsp02.12.2015

Illustrated instructions

Instructions

Reaferon-LIPINT® (Reaferon-Lipint®)